Ignite Creation Date:
2024-05-05 @ 6:40 PM
Last Modification Date:
2024-10-26 @ 9:36 AM
Study NCT ID:
NCT00526045
Status:
COMPLETED
Last Update Posted:
2020-12-17
First Post:
2007-09-05
Brief Title:
Phase I-II Study to Determine the Maximum Tolerated Dose MTD of AUY922 in Advanced Solid Malignancies and Efficacy in HER2 or ER Locally Advanced or Metastatic Breast Cancer Patients
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis